10.86
price down icon0.55%   -0.06
after-market After Hours: 10.86
loading
Tyra Biosciences Inc stock is traded at $10.86, with a volume of 224.32K. It is down -0.55% in the last 24 hours and up +13.24% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$10.92
Open:
$10.96
24h Volume:
224.32K
Relative Volume:
0.68
Market Cap:
$576.56M
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-6.7453
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
+6.05%
1M Performance:
+13.24%
6M Performance:
-32.92%
1Y Performance:
-45.97%
1-Day Range:
Value
$10.82
$11.31
1-Week Range:
Value
$9.965
$11.31
52-Week Range:
Value
$6.42
$29.60

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name
Name
Tyra Biosciences Inc
Name
Phone
(619) 728-4760
Name
Address
2656 STATE STREET, CARLSBAD
Name
Employee
60
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
TYRA's Discussions on Twitter

Compare TYRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TYRA
Tyra Biosciences Inc
10.86 544.54M 0 -83.74M -64.98M -1.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.27 123.14B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
550.00 60.43B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.69 42.07B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
572.71 34.47B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
290.35 27.42B 3.81B -644.79M -669.77M -6.24

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-21-25 Resumed Piper Sandler Overweight
Jan-07-25 Initiated UBS Buy
Oct-18-24 Upgrade BofA Securities Neutral → Buy
Aug-15-24 Initiated Piper Sandler Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Jun-30-23 Initiated Wedbush Outperform
Feb-03-23 Initiated Oppenheimer Outperform
Jun-23-22 Initiated H.C. Wainwright Buy
Mar-08-22 Upgrade Jefferies Hold → Buy
Nov-08-21 Downgrade Jefferies Buy → Hold
Oct-11-21 Initiated BofA Securities Buy
Oct-11-21 Initiated Cowen Outperform
Oct-11-21 Initiated Jefferies Buy
View All

Tyra Biosciences Inc Stock (TYRA) Latest News

pulisher
Jul 16, 2025

Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Tyra Biosciences Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Tyra Biosciences Inc. stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Tyra Biosciences Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com

Jul 14, 2025
pulisher
Jul 13, 2025

Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Jul 13, 2025
pulisher
Jul 09, 2025

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress

Jul 09, 2025
pulisher
Jul 09, 2025

Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan

Jul 08, 2025
pulisher
Jul 08, 2025

Where are the Opportunities in (TYRA) - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 02, 2025

Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jul 02, 2025
pulisher
Jul 01, 2025

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology

Jul 01, 2025
pulisher
Jun 30, 2025

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal

Jun 30, 2025
pulisher
Jun 30, 2025

Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Revolutionary Oral Treatment for Bladder Cancer Begins Phase 2 Trial: First Patient Receives TYRA-300 - Stock Titan

Jun 30, 2025
pulisher
Jun 17, 2025

When the Price of (TYRA) Talks, People Listen - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail

Jun 16, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Sells 2,366 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 10,426 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

RA Capital Boosts Stake in Tyra Biosciences (TYRA) to 22.4% | TYRA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

June Brings on Some Huge Insider Buying - 24/7 Wall St.

Jun 11, 2025
pulisher
Jun 10, 2025

Kernaghan buying at Western Forest Products (WEF) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Has $643,000 Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Tyra Biosciences Soars 10.71% on Insider Buying - AInvest

Jun 09, 2025
pulisher
Jun 08, 2025

Two Sigma Investments LP Grows Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Acquires Shares of 26,297 Skillz Inc. (NYSE:SKLZ) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Schwab International Equity ETF (NYSEARCA:SCHF) Shares Sold by Squarepoint Ops LLC - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Zumiez Inc. (NASDAQ:ZUMZ) Shares Sold by Two Sigma Investments LP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Invests $253,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Purchases 92,800 Shares of ThredUp Inc. (NASDAQ:TDUP) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Takes $162,000 Position in Innovex International, Inc. (NYSE:INVX) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Makes New $171,000 Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Bank of America Corp DE Purchases 11,804 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Klondike Silver (CVE:KS) Trading Up 50% – What’s Next? - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of “Buy” from Analysts - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Wishbone Gold (LON:WSBN) Trading 21.6% Higher – Should You Buy? - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

AGM Group (NASDAQ:AGMH) Rating Increased to Hold at Wall Street Zen - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Buy” from Analysts - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

BlackRock MuniYield Michigan Quality Fund, Inc. (NYSE:MIY) Short Interest Up 21.4% in May - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Motorcar Parts of America, Inc. (NASDAQ:MPAA) Shares Sold by Two Sigma Advisers LP - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Trend Tracker for (TYRA) - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 05, 2025

PortfolioPlus S&P 500 ETF (NYSEARCA:PPLC) Shares Up 2.2% – What’s Next? - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Purchases New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Acquires 6,466 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

May 30, 2025
pulisher
May 29, 2025

Tyra Bioscience Holds 2025 Annual Stockholders Meeting - TipRanks

May 29, 2025
pulisher
May 28, 2025

TYRA Stock: Upcoming Oppenheimer Meeting Announcement | TYRA Sto - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bank of America Corp DE Sells 1,164,431 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

May 28, 2025

Tyra Biosciences Inc Stock (TYRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.01
price up icon 0.64%
$35.47
price down icon 0.37%
$104.17
price down icon 0.40%
$27.63
price down icon 2.26%
$111.04
price down icon 1.29%
biotechnology ONC
$290.35
price up icon 4.01%
Cap:     |  Volume (24h):